Artwork

Content provided by Clinical Care Options, LLC and Clinical Care Options. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Clinical Care Options, LLC and Clinical Care Options or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
Player FM - Podcast App
Go offline with the Player FM app!

Omicron Variant: Effects on Treatments for COVID-19

41:54
 
Share
 

Manage episode 318562257 series 2884624
Content provided by Clinical Care Options, LLC and Clinical Care Options. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Clinical Care Options, LLC and Clinical Care Options or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.

The SARS-CoV-2 omicron variant has affected which of our COVID-19 treatment strategies are currently effective, with some expected to maintain their efficacy and some expected to lose their efficacy. In this episode, Arthur Kim, MD, discusses the effects of the SARS-CoV-2 omicron variant on many of the COVID-19 approved, authorized, and investigational treatment options, including:

  • Direct-acting, small-molecule antiviral agents such as molnupiravir, nirmatrelvir + ritonavir, and remdesivir
  • Monoclonal antibody treatments such as bamlanivimab + etesevimab, casirivimab + imdevimab, cilgavimab + tixagevimab, regdanvimab, and sotrovimab

Presenter:

Arthur Kim, MD
Associate Professor
Department of Medicine
Harvard Medical School
Director, Viral Hepatitis Clinic
Division of Infectious Diseases
Massachusetts General Hospital
Boston, Massachusetts

Review the downloadable slidesets at:
https://bit.ly/3FXc90w
https://bit.ly/32tp2BT

Link to full program:
https://bit.ly/3Ix8uZg

  continue reading

378 episodes

Artwork
iconShare
 
Manage episode 318562257 series 2884624
Content provided by Clinical Care Options, LLC and Clinical Care Options. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Clinical Care Options, LLC and Clinical Care Options or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.

The SARS-CoV-2 omicron variant has affected which of our COVID-19 treatment strategies are currently effective, with some expected to maintain their efficacy and some expected to lose their efficacy. In this episode, Arthur Kim, MD, discusses the effects of the SARS-CoV-2 omicron variant on many of the COVID-19 approved, authorized, and investigational treatment options, including:

  • Direct-acting, small-molecule antiviral agents such as molnupiravir, nirmatrelvir + ritonavir, and remdesivir
  • Monoclonal antibody treatments such as bamlanivimab + etesevimab, casirivimab + imdevimab, cilgavimab + tixagevimab, regdanvimab, and sotrovimab

Presenter:

Arthur Kim, MD
Associate Professor
Department of Medicine
Harvard Medical School
Director, Viral Hepatitis Clinic
Division of Infectious Diseases
Massachusetts General Hospital
Boston, Massachusetts

Review the downloadable slidesets at:
https://bit.ly/3FXc90w
https://bit.ly/32tp2BT

Link to full program:
https://bit.ly/3Ix8uZg

  continue reading

378 episodes

All episodes

×
 
Loading …

Welcome to Player FM!

Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.

 

Quick Reference Guide